US 12,134,601 B2
Compounds for inhibiting LY6K and methods of using same
Geeta Upadhyay, Washington, DC (US)
Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Appl. No. 16/762,424
Filed by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
PCT Filed Nov. 9, 2018, PCT No. PCT/US2018/060121
§ 371(c)(1), (2) Date May 7, 2020,
PCT Pub. No. WO2019/094788, PCT Pub. Date May 16, 2019.
Claims priority of provisional application 62/583,998, filed on Nov. 9, 2017.
Prior Publication US 2021/0009522 A1, Jan. 14, 2021
Int. Cl. C07D 219/10 (2006.01); C07C 39/15 (2006.01)
CPC C07D 219/10 (2013.01) [C07C 39/15 (2013.01)] 8 Claims
 
1. A method for inhibiting Ly6K protein in a subject in need thereof, comprising administering to the subject:
(i) an effective amount of a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or
(ii) an effective amount of a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or
(iii) an effective amount of a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and
an effective amount of a compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein the effective amount is sufficient to lower activity of the Ly6k protein in the subject.